Academic Journal
1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20
| العنوان: | 1214P High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from a phase II multicenter study, POSITION20 |
|---|---|
| المؤلفون: | Zwierenga, F., van Veggel, B.A.M.H., Hendriks, L.E.L., Hiltermann, T.J.N., Hiddinga, B.I., Hijmering-Kappelle, L.B.M., Dingemans, A-M.C., van der Leest, C., de Langen, A.J., van den Heuvel, M., van der Wekken, A.J. |
| المصدر: | Annals of Oncology ; volume 32, page S966 ; ISSN 0923-7534 |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2021 |
| المجموعة: | ScienceDirect (Elsevier - Open Access Articles via Crossref) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1016/j.annonc.2021.08.1819 |
| الاتاحة: | http://dx.doi.org/10.1016/j.annonc.2021.08.1819 https://api.elsevier.com/content/article/PII:S0923753421040497?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S0923753421040497?httpAccept=text/plain |
| Rights: | https://www.elsevier.com/tdm/userlicense/1.0/ ; http://www.elsevier.com/open-access/userlicense/1.0/ |
| رقم الانضمام: | edsbas.FD92E6F4 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.annonc.2021.08.1819 |
|---|